<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110339</url>
  </required_header>
  <id_info>
    <org_study_id>HCAECV01</org_study_id>
    <nct_id>NCT05110339</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexmedetomidine on Postoperative Analgesia</brief_title>
  <acronym>EDPARMRCT</acronym>
  <official_title>Efficacy of Dexmedetomidine on Postoperative Analgesia After Radical Mastectomy: Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad autónoma de Tamaulipas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad autónoma de Tamaulipas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, double-blind study is designed to evaluate the postoperative&#xD;
      analgesic efficacy of dexmedetomidine as an adjunct to ropivacaine in erector spinae block in&#xD;
      patients undergoing radical mastectomy. The investigators hypothesis is that the&#xD;
      administration of ropivacaine 0.5% associated with dexmedetomidine in the blockade via the&#xD;
      plane in the erector spinae is less effective in controlling acute postoperative pain in&#xD;
      radical mastectomy than the administration of ropivacaine 0.5% without dexmedetomidine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing radical mastectomy are randomly assigned to receive, in addition to&#xD;
      standard general anesthesia, a block of the erector spinae plane with ropivacaine at a dose&#xD;
      of 0.5% for the control group (n = 13) and ropivacaine at a dose of 0.5% more dexmedetomidine&#xD;
      at 0.3 mcg kg (n = 15) for the intervention group. General anesthesia was induced using&#xD;
      anxiolysis with midazolam at 30 mcg / kg corrected weight, as induction, propofol at a dose&#xD;
      of 1.5 - 2 mg kg, opioid analgesia with fentanyl at a dose of 3 mcg / kg weight corrected&#xD;
      with 30% according to ideal weight initial bolus dose, and dose as required, neuromuscular&#xD;
      relaxation with cisatracurium at a dose of 0.1 mg / kg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized double-blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The outcome assessor did not know the allocation of the participants. The patient is not informed of the medication used in the erector spinae block.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain score</measure>
    <time_frame>0 hours</time_frame>
    <description>The intensity of pain is evaluated by the visual analog scale (VAS) that measures pain severity expressed on a numerical scale of 0-10: 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain score</measure>
    <time_frame>6 hours</time_frame>
    <description>The intensity of pain is evaluated by the visual analog scale (VAS) that measures pain severity expressed on a numerical scale of 0-10: 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain score</measure>
    <time_frame>12 hours</time_frame>
    <description>The intensity of pain is evaluated by the visual analog scale (VAS) that measures pain severity expressed on a numerical scale of 0-10: 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Pain score</measure>
    <time_frame>24 hours</time_frame>
    <description>The intensity of pain is evaluated by the visual analog scale (VAS) that measures pain severity expressed on a numerical scale of 0-10: 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Additional opioid-type drugs</measure>
    <time_frame>24 hours</time_frame>
    <description>The presence of additional opioid analgesic requirements will be evaluated. All patients will be prescribed intravenous analgesia on a strict schedule as follows: ketorolac 30mg in intravenous infusion every 8 hours.&#xD;
If the follow-up assessment of postoperative pain is greater than or equal to 4 in the VAS, additional medication is indicated, which is considered as analgesic rescue and which consists of buprenorphine at a dose of 2 mcg kg corrected with 30% according to ideal weight intravenously in both groups, with a dose no greater than 6 mcg / kg / day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>24 hours</time_frame>
    <description>Incidence of postoperative nausea and vomiting (%)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Ropivacaine plus Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg corrected in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In addition to standard general anesthesia, patients receive erector spinae block with ropivacaine at a dose of 0.5% in a volume of 20 ml at the level of thoracic vertebra number 4, guided with ultrasound and under sterile technique, the date and time of application are recorded on the data collection sheet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine plus dexmedetomidine</intervention_name>
    <description>Erector spinae block with ropivacaine at a dose of 0.5% plus dexmedetomidine at 0.3 mcg / kg.</description>
    <arm_group_label>Ropivacaine plus Dexmedetomidine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Erector spinae block with ropivacaine at a dose of 0.5%.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing radical mastectomy for pathology &quot;breast cancer&quot;&#xD;
&#xD;
          -  Patient undergoing anesthetic technique due to erector spinae plane block&#xD;
&#xD;
          -  Informed consent to perform the anesthesia technique.&#xD;
&#xD;
          -  Karnofsky&gt; 80 points&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency surgery&#xD;
&#xD;
          -  Patient with mental pathology that prevents pain assessment.&#xD;
&#xD;
          -  Rejection of anesthetic technique.&#xD;
&#xD;
          -  Patient with allergy to local anesthetics&#xD;
&#xD;
          -  Patient with local infection of the puncture site for application of the erector&#xD;
             spinae block&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jose Camilo Muñoz Chaves</name>
      <address>
        <city>Matamoros</city>
        <state>Tamaulipas</state>
        <zip>87000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

